SLC5A2 and type 2 diabetes mellitus: In this cohort study in Taiwan including 10 038 patients with T2D newly receiving SGLT2 inhibitors, there was a significant risk reduction in the incidence of dry eye diseases compared with 1077 propensity score–weighted patients with T2D newly receiving GLP-1 RAs.